ABVX Share Price Performance
€109.40
102.55 (1,497.08%)
23.6% undervalued intrinsic discount
€143.25
Fair Value
Price €109.40
Vestra €143.25
Fair Value€143.25
Share Pricen/a
ABIVAX Société Anonyme Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 18 Fair Values set on narratives written by author
ABVX Community Narratives
VE
Fair Value €143.25 23.6% undervalued intrinsic discount
Abivax S.A. (ABVX): The "First-in-Class" miR-124 Play and the M&A Data Room
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
Abivax S.A. (ABVX): The "First-in-Class" miR-124 Play and the M&A Data Room
Abivax (ABVX) is currently one of the most high-conviction "momentum" stories in the biotechnology sector as of March 19, 2026. After a massive 1,800% run in 2025, the stock closed today at $123.99 USD , following a week of intense speculation and institutional accumulation.Read more
19
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
Trending Discussion
Recently Updated Narratives
VE
Abivax S.A. (ABVX): The "First-in-Class" miR-124 Play and the M&A Data Room
Fair Value: €143.25 23.6% undervalued intrinsic discount
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
ABIVAX Société Anonyme Key Details
Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
Mar 23, 2026
- -3.77
- 100.00%
- -5,526.64%
- 14.2%
About ABVX
- Founded
- 2013
- Employees
- 67
- CEO
- WebsiteView website
ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod that is in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis, as well as in Phase 2b clinical trial to treat patients with Crohn’s disease. The company was incorporated in 2013 and is headquartered in Paris, France.
